공개특허 10-2011-0091780 T-세포 림프종, Degos 질환, 융기성 피부섬유육종, 유피낭종, 복부 결합조직형성 소원형세포 종양, 미만성 거대 B 세포 림프종, 배아형성장애 신경상피 종양, 배아 암종, 내배엽동 종양, 자궁내막 암, 자궁내막 자궁 암, 자궁 내막양 종양, 장병증 연관 T-세포 림프종, 상의모세포종, 상의세포종, 상피양 육종, 적백혈병, 식도 암, 감각신 경모세포종, 유잉 계통 종양, 유잉 계통 육종, 유잉 육종, 두개외 생식세포 종양, 생식샘외 생식세포 종양, 간 외 담도 암, 유방외성 파제트병, 난관 암, 태아속 태아, 섬유종, 섬유육종, 소포성 림프종, 소포성 갑상선 암, 담낭 암, 담낭 암, 신경절교종, 신경절신경종, 위 암, 위 림프종, 위장 암, 위장 유암종, 위장 기질 종양, 위장 기질 종양, 생식세포 종양, 배세포종, 임신성 융모막암종, 임신성 융모성 종양, 뼈의 거대 세포 종양, 다형성교 모세포종, 신경교종, 대뇌신경교종증, 사구 종양, 글루카곤종, 생식아세포종, 과립층 세포 종양, 모상 세포 백 혈병, 모상 세포 백혈병, 두경부 암, 두경부 암, 심장 암, 혈관모세포종, 혈관주위세포종, 혈관육종, 혈액학적 악성, 간세포 암종, 간비 T-세포 림프종, 유전성 유방-난소암 증후군, 호지킨 림프종, 호지킨 림프종, 하인두 암, 시상하부 신경교종, 염증 유방암, 안구내 흑색종, 섬 세포 암종, 섬 세포 종양, 연소형 골수단구성 백혈병, 카포시 육종, 카포시 육종, 신장 암, 클라츠킨씨 종양, 크루켄버그 종양, 후두 암, 후두 암, 악성 흑자 흑색종, 백혈병, 백혈병, 입술과 구강 암, 지방육종, 폐암, 황체종, 림프관종, 림프관육종, 림프상피종, 림프성 백혈병, 림프종, 마크로글로불린혈증, 악성 섬유성 조직구종, 악성 섬유성 조직구종, 뼈의 악성 섬유성 조직구종, 악성 신경교종, 악성 중피종, 악성 말초신경초 종양, 악성 횡문근양 종양, 악성 트리톤 종양, MALT 림프종, 덮개 세 포 림프종, 비만 세포 백혈병, 종격동 생식세포 종양, 종격동 종양, 갑상선 수질암, 속질모세포종, 속질모세포 종, 속질상피종, 흑색종, 흑색종, 수막종, 메르켈 세포 암종, 중피종, 중피종, 잠복원발성 전이성 편평 목 암, 전이성 요로상피 암종, 혼합 뮬러 종양, 단구성 백혈병, 구강 암, 점액 종양, 다발성 내분비 종양 증후군, 다발 성 골수종, 다발성 골수종, 균상식육종, 균상식육종, 골수형성이상 질환, 골수형성이상 증후군, 골수성 백혈병, 골수성 육종, 골수증식 질환, 점액종, 비강 암, 코인두 암, 코인두 암종, 신생물, 신경집종, 신경모세포종, 신 경모세포종, 신경섬유종, 신경종, 결절성 흑색종, 비-호지킨 림프종, 비-호지킨 림프종, 비-흑색종 피부 암, 비 -소세포 폐암, 안종양, 희소별아교세포종, 핍지교종, 호산성세포종, 시신경초 수막종, 구강 암, 구강 암, 입인 두 암, 골육종, 골육종, 난소암, 난소암, 난소 상피 암, 난소 생식세포 종양, 난소 저급성 악성 종양, 유방의 파제트병, 판코스트 종양, 췌장암, 췌장암, 갑상샘 유두 암, 유두종증, 곁신경절종, 부비동 암, 부갑상선 암, 음경 암, 혈관주위 상피모양 세포 종양, 인두 암, 갈색세포종, 중간 분화의 송과체 실질 종양, 송과체모세포종, 하수체세포종, 뇌하수체 선종, 뇌하수체 종양, 플라스마 세포 신생물, 흉막폐아세포종, 다배아종, 전구 T-림프 모구성 림프종, 원발성 중추신경계 림프종, 원발성 삼출성 림프종, 원발성 간세포 암, 원발성 간 암, 원발성 복 막 암, 원시 신경외배엽 종양, 전립선암, 복막가성점액종, 직장 암, 신장 세포 암종, 염색체 15에서 NUT 유전자 가 관련된 호흡기 암종, 망막모세포종, 횡문근종, 횡문근육종, 리히터 변형, 천미골 기형종, 타액선 암, 육종, 다발성신경초종, 피지선 암종, 속발성 신생물, 정상피종, 장액 종양, 세르톨리 라이디히 세포 종양, 성삭-기질 종양, 세자리 증후군, 인환 세포 암종, 피부 암, 청색 소원형세포 종양, 소세포 암종, 소세포 폐암, 소세포 림 프종, 소장 암, 연부 조직 육종, 소마토스타틴종, 매연 사마귀, 척추 종양, 척추 종양, 비장 번연 림프종, 편평 세포 암종, 위 암, 표재 확장성 흑색종, 천막위 원시 신경외배엽 종양, 표면 상피-기질 종양, 활액 육종, T-세 포 급성 림프모구성 백혈병, T-세포 큰 과립성 림프구 백혈병, T-세포 백혈병, T-세포 림프종, T-세포 전림프성 백혈병, 기형종, 말기 림프성 암, 고환 암, 난포막종, 인후 암, 흉선 암종, 가슴샘종, 갑상선 암, 신우 요관의 이행 세포 암, 이행 세포 암종, 요막관 암, 요도 암, 비뇨생식기 신생물, 자궁 육종, 포도막 흑색종, 질 암, 버 너-모리슨 증후군, 사마귀모양 암종, 시각경로 신경교종, 외음부 암, 왈덴스트룀 마크로글로불린혈증, 바르틴 종양, 윌름 종양, 또는 이들의 임의의 조합, 그리고 암 화학요법에서 약물 내성 및 암 화학요법 독성이 포함되 지만 이들에 국한되지 않는다(참조: Hirata T, et al, Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro, Leuk Res., 2003 Apr;27(4):343-9, Bataille R, et al, Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma, Blood, <strong>19</strong>95 Jul 15;86 (2):685-91; Goto H, et al, Mouse anti-human interleukin-6 receptor monoclonal antibody inhibits proliferation of fresh human myeloma cells in vitro, Jpn J Cancer Res., <strong>19</strong>94 Sep;85(9):958-65; Klein B, et al, Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia, Blood, <strong>19</strong>91 Sep 1;78(5):1<strong>19</strong>8-204; Mauray S, et al, Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6, Eur J Immunol., 2000 Jul;30(7):2065-73; Tsunenari T, et al, New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor, Blood, <strong>19</strong>97 Sep 15;90(6):2437- 44; Emilie D, et al, Interleukin-6 production in high-grade B lymphomas: correlation with the presence of malignant immunoblasts in acquired immunodeficiency syndrome and in human immunodeficiency virus- seronegative patients, Blood, <strong>19</strong>92 Jul 15;80(2):498-504; Emilie D, et al, Administration of an anti- - <strong>12</strong>6 -
[<strong>12</strong>01] interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical Symptoms, Blood, <strong>19</strong>94 Oct 15; 84(8):2472-9; Smith PC, et al, Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice, Prostate, 2001 Jun 15;48(1):47-53; Smith PC, et al, Interleukin-6 and prostate cancer progression, Cytokine Growth Factor Rev., 2001 Mar;<strong>12</strong>(1):33-40; Chung TD, et al, Characterization of the role of IL-6 in the progression of prostate cancer, Prostate, <strong>19</strong>99 Feb 15;38(3):<strong>19</strong>9-207; Okamoto M, et al, Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro, Cancer Res., <strong>19</strong>97 Jan 1;57(1):141-6; Reittie JE, et al, Interleukin-6 inhibits apoptosis and tumor necrosis factor induced proliferation of B-chronic lymphocytic leukemia, Leuk Lymphoma, <strong>19</strong>96 Jun;22(1-2):83-90, follow 186, color plate VI; Sugiyama H, et al, The expression of IL-6 and its related genes in acute leukemia, Leuk Lymphoma, <strong>19</strong>96 Mar;21(1-2):49-52; Bataille R, et al, Effects of an anti-interleukin-6 (IL-6) murine monoclonal antibody in a patient with acute monoblastic leukemia, Med Oncol Tumor Pharmacother., <strong>19</strong>93;10(4):185-8; Kedar I, et al, Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy, Int J Cancer, 2004 Jun 10;110(2):260-5; Angelo LS, Talpaz M, Kurzrock R, Autocrine interleukin-6 production in renal cell carcinoma: evidence for the involvement of p53, Cancer Res., 2002 Feb 1;62(3):932-40; Nishimoto N, Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease, Blood, 2005 Oct 15;106(8):2627-32, Epub 2005 Jul 5; Katsume A, et al, Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice, Cytokine, 2002 Dec 21;20(6):304-11; Nishimoto N, et al, Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy, Blood, 2000 Jan 1;95(1):56-61; Screpanti I, Inactivation of the IL-6 gene prevents development of multicentric Castleman's disease in C/EBP betamice, J Exp Med., <strong>19</strong>96 Oct 1;184(4):1561-6; Hsu SM, et al, Expression of interleukin-6 in Castleman's disease, Hum Pathol., <strong>19</strong>93 Aug;24(8):833-9; Yoshizaki K, et al, Pathogenic significance of interleukin-6 (IL 6/BSF-2) in Castleman's disease, Blood, <strong>19</strong>89 Sep;74(4):1360-7; Nilsson MB, et al, Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine, Cancer Res., 2005 Dec 1;65(23):10794-800; Toutirais O, et al, Constitutive expression of TGF-betal, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma, Eur Cytokine Netw., 2003 Oct-Dec;14(4):246-55; Obata NH, et al, Effects of interleukin 6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma, Anticancer Res., <strong>19</strong>97 Jan-Feb;17 (lA):337-42; Dedoussis GV, et al, Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line, Exp Cell Res., <strong>19</strong>99 Jun 15;249(2):269-78; Borsellino N, et al, Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity, Cancer, <strong>19</strong>99 Jan 1;85(1):134-44; Borsellino N, et al, Endogenous interleukin 6 is a resistance factor for cis- diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines, Cancer Res., <strong>19</strong>95 Oct 15;55(20):4633-9; Mizutani Y, et al, Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti- interleukin 6 receptor monoclonal antibody; Cancer Res., <strong>19</strong>95 Feb 1;55(3):590-6; Yusuf RZ, et al, Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation, Curr Cancer Drug Targets, 2003 Feb;3(1):1-<strong>19</strong>; Duan Z, et al, Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-20S human osteosarcoma cells, Cytokine, 2002 Mar 7;17(5):234-42; Conze D, et al, Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells, Cancer Res., 2001 Dec 15;61(24):8851-8; Rossi JF, et al, Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects, Bone Marrow Transplant, 2005 Nov;36(9):771-9; 그리고 Tonini G, et al, Oxaliplatin may induce cytokine-release syndrome in colorectal cancer patients, J BiolRegul Homeost Agents, 2002 Apr-Jun;16 (2):105-9; 이들 각각의 내용은 본 발명에 그 전체가 참조로서 편입된다). 공개특허 10-2011-0091780 본 발명의 또 다른 구체예에서, 본 명세서에서 기술된 항-IL-6 항체, 또는 이들의 단편은 허혈성 심장 질환, 동 - <strong>12</strong>7 -
- Page 1 and 2:
(51) Int. Cl. (19) 대한민국특
- Page 3 and 4:
특허청구의 범위 청구항 1
- Page 5 and 6:
것을 특징으로 하는 방법.
- Page 7 and 8:
공개특허 10-2011-0091780 속질
- Page 9 and 10:
청구항 35 청구항 1에 있어
- Page 11 and 12:
으로 하는 방법. 청구항 55
- Page 13 and 14:
[0003] [0004] [0005] [0006] [0007]
- Page 15 and 16:
[0019] [0020] [0021] [0022] [0023]
- Page 17 and 18:
[0029] [0030] [0031] [0032] [0033]
- Page 19 and 20:
[0042] [0043] [0044] [0045] [0046]
- Page 21 and 22:
[0059] [0060] [0061] [0062] [0063]
- Page 23 and 24:
[0080] [0081] [0082] [0083] [0084]
- Page 25 and 26:
[0110] [0111] [0112] [0113] [0114]
- Page 27 and 28:
[0125] [0126] [0127] [0128] [0129]
- Page 29 and 30:
[0143] [0144] [0145] [0146] [0147]
- Page 31 and 32:
[0156] [0157] [0158] [0159] [0160]
- Page 33 and 34:
[0168] [0169] [0170] [0171] [0172]
- Page 35 and 36:
[0192] [0193] [0194] [0195] [0196]
- Page 37 and 38:
[0218] [0219] [0220] [0221] [0222]
- Page 39 and 40:
[0246] [0247] [0248] [0249] [0250]
- Page 41 and 42:
[0270] [0271] [0272] [0273] [0274]
- Page 43 and 44:
[0296] [0297] [0298] [0299] [0300]
- Page 45 and 46:
[0324] [0325] [0326] [0327] [0328]
- Page 47 and 48:
[0349] [0350] [0351] [0352] [0353]
- Page 49 and 50:
[0375] [0376] [0377] [0378] [0379]
- Page 51 and 52:
[0402] [0403] [0404] [0405] [0406]
- Page 53 and 54:
[0428] [0429] [0430] [0431] [0432]
- Page 55 and 56:
[0455] [0456] [0457] [0458] [0459]
- Page 57 and 58:
[0480] [0481] [0482] [0483] [0484]
- Page 59 and 60:
[0505] [0506] [0507] [0508] [0509]
- Page 61 and 62:
[0533] [0534] [0535] [0536] [0537]
- Page 63 and 64:
[0558] [0559] [0560] [0561] [0562]
- Page 65 and 66:
[0578] [0579] [0580] [0581] [0582]
- Page 67 and 68:
[0623] [0624] [0625] [0626] [0627]
- Page 69 and 70:
[0675] [0676] [0677] [0678] [0679]
- Page 71 and 72:
[0707] 표 1 - 71 - 공개특허 10
- Page 73 and 74:
[0709] [0710] [0711] [0712] [0713]
- Page 75 and 76: [0723] [0724] [0725] [0726] [0727]
- Page 77 and 78: [0738] [0739] [0740] [0741] [0742]
- Page 79 and 80: [0752] [0753] [0754] [0755] [0756]
- Page 81 and 82: [0772] [0773] [0774] [0775] [0776]
- Page 83 and 84: [0793] [0794] [0795] [0796] [0797]
- Page 85 and 86: [0815] [0816] [0817] [0818] [0819]
- Page 87 and 88: [0836] [0837] [0838] [0839] [0840]
- Page 89 and 90: [0858] [0859] [0860] [0861] [0862]
- Page 91 and 92: [0881] [0882] [0883] [0884] [0885]
- Page 93 and 94: [0903] [0904] [0905] [0906] [0907]
- Page 95 and 96: [0926] [0927] [0928] [0929] [0930]
- Page 97 and 98: [0948] [0949] [0950] [0951] [0952]
- Page 99 and 100: [0969] [0970] [0971] [0972] [0973]
- Page 101 and 102: [0992] [0993] [0994] [0995] [0996]
- Page 103 and 104: [1014] [1015] [1016] [1017] [1018]
- Page 105 and 106: [1023] [1024] 을 지칭한다. 이
- Page 107 and 108: [1032] [1033] [1034] [1035] [1036]
- Page 109 and 110: [1052] [1053] [1054] [1055] [1056]
- Page 111 and 112: [1074] [1075] [1076] [1077] [1078]
- Page 113 and 114: [1093] [1094] [1095] [1096] [1097]
- Page 115 and 116: [1112] [1113] [1114] [1115] [1116]
- Page 117 and 118: [1146] [1147] [1148] [1149] [1150]
- Page 119 and 120: [1163] [1164] [1165] [1166] [1167]
- Page 121 and 122: [1179] [1180] [1181] [1182] [1183]
- Page 123 and 124: [1197] [1198] trained male runners,
- Page 125: [1199] [1200] 8; Lange, A., et al,
- Page 129 and 130: [1202] [1203] [1204] [1205] [1206]
- Page 131 and 132: [1210] [1211] [1212] [1213] [1214]
- Page 133 and 134: 의 웰(well) 중에서 9개가 항
- Page 135 and 136: [1238] [1239] [1240] [1241] [1242]
- Page 137 and 138: [1255] [1256] [1257] [1258] [1259]
- Page 139 and 140: [1273] [1274] [1275] [1276] [1277]
- Page 141 and 142: [1289] [1290] [1291] [1292] [1293]
- Page 143 and 144: [1313] [1314] [1315] [1316] [1317]
- Page 145 and 146: [1335] [1336] [1337] [1338] [1339]
- Page 147 and 148: [1358] [1359] [1360] [1361] [1362]
- Page 149 and 150: [1390] [1391] [1392] [1393] [1394]
- Page 151 and 152: [1431] [1432] [1433] [1434] [1435]
- Page 153 and 154: [1491] [1492] [1493] [1494] [1495]
- Page 155 and 156: [1549] [1550] [1551] [1552] [1553]
- Page 157 and 158: [1607] [1608] [1609] [1610] [1611]
- Page 159 and 160: [1669] [1670] [1671] [1672] [1673]
- Page 161 and 162: [1729] [1730] [1731] [1732] [1733]
- Page 163 and 164: [1789] [1790] [1791] [1792] [1793]
- Page 165 and 166: [1849] [1850] [1851] [1852] [1853]
- Page 167 and 168: [1910] [1911] [1912] [1913] [1914]
- Page 169 and 170: [1971] [1972] [1973] [1974] [1975]
- Page 171 and 172: [2031] [2032] [2033] [2034] [2035]
- Page 173 and 174: [2091] [2092] [2093] [2094] [2095]
- Page 175 and 176: [2151] [2152] [2153] [2154] [2155]
- Page 177 and 178:
[2213] [2214] [2215] [2216] [2217]
- Page 179 and 180:
[2275] [2276] [2277] [2278] [2279]
- Page 181 and 182:
[2335] [2336] [2337] [2338] [2339]
- Page 183 and 184:
[2395] [2396] [2397] [2398] [2399]
- Page 185 and 186:
[2455] [2456] [2457] [2458] [2459]
- Page 187 and 188:
[2517] [2518] [2519] [2520] [2521]
- Page 189 and 190:
[2577] [2578] [2579] [2580] [2581]
- Page 191 and 192:
[2637] [2638] [2639] [2640] [2641]
- Page 193 and 194:
[2708] [2709] [2710] [2711] [2712]
- Page 195 and 196:
[2755] [2756] [2757] [2758] [2759]
- Page 197 and 198:
[2795] [2796] [2797] [2798] [2799]
- Page 199 and 200:
[2825] [2826] [2827] [2828] [2829]
- Page 201 and 202:
도면 도면1 - 201 - 공개특허
- Page 203 and 204:
도면3 - 203 - 공개특허 10-201
- Page 205 and 206:
도면5 - 205 - 공개특허 10-201
- Page 207 and 208:
도면7 - 207 - 공개특허 10-201
- Page 209 and 210:
도면9 - 209 - 공개특허 10-201
- Page 211 and 212:
도면10b - 211 - 공개특허 10-2
- Page 213 and 214:
도면10d - 213 - 공개특허 10-2
- Page 215 and 216:
도면11 - 215 - 공개특허 10-20
- Page 217 and 218:
도면13 - 217 - 공개특허 10-20
- Page 219 and 220:
도면15 - 219 - 공개특허 10-20
- Page 221 and 222:
도면17 - 221 - 공개특허 10-20
- Page 223 and 224:
도면19 - 223 - 공개특허 10-20
- Page 225 and 226:
도면21 - 225 - 공개특허 10-20
- Page 227 and 228:
도면23 - 227 - 공개특허 10-20
- Page 229 and 230:
도면25 - 229 - 공개특허 10-20
- Page 231 and 232:
도면26b - 231 - 공개특허 10-2
- Page 233 and 234:
도면28 - 233 - 공개특허 10-20
- Page 235 and 236:
도면30 - 235 - 공개특허 10-20
- Page 237 and 238:
도면32 - 237 - 공개특허 10-20
- Page 239 and 240:
도면34a - 239 - 공개특허 10-2
- Page 241 and 242:
도면35a - 241 - 공개특허 10-2
- Page 243 and 244:
도면36a - 243 - 공개특허 10-2
- Page 245 and 246:
도면37a - 245 - 공개특허 10-2
- Page 247 and 248:
도면38 도면39 - 247 - 공개특
- Page 249 and 250:
도면41 - 249 - 공개특허 10-20
- Page 251 and 252:
도면43 - 251 - 공개특허 10-20
- Page 253 and 254:
도면45 - 253 - 공개특허 10-20
- Page 255 and 256:
2009-11-24 61/117,861 2008-11-25
- Page 257 and 258:
100 105 110 Gly Tyr Ser Leu Arg Asn
- Page 259 and 260:
PRT Oryctolagus cuniculus 8 Ile I
- Page 261 and 262:
48 DNA Oryctolagus cuniculus 16
- Page 263 and 264:
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln
- Page 265 and 266:
1 5 10 24 7 PRT Oryctolagus cun
- Page 267 and 268:
DNA Oryctolagus cuniculus 31 cagg
- Page 269 and 270:
38 Met Glu Thr Gly Leu Arg Trp Leu
- Page 271 and 272:
45 496 DNA Oryctolagus cuniculus
- Page 273 and 274:
PRT Oryctolagus cuniculus 53 Met
- Page 275 and 276:
Gly Ala Ser Thr Leu Asp Ser 1 5 57
- Page 277 and 278:
21 DNA Oryctolagus cuniculus 64
- Page 279 and 280:
Gly Thr Pro Leu Thr Leu Thr Cys Thr
- Page 281 and 282:
acatttgccc aagtgctgac ccagactcca tc
- Page 283 and 284:
Leu Pro Gly Ala Thr Phe Ala Ala Val
- Page 285 and 286:
89 Leu Gly Gly Tyr Asp Asp Asp Ala
- Page 287 and 288:
caggcatcca aactggcatc t 21 97 33
- Page 289 and 290:
Trp Ile Gly Met Ile Tyr Gly Ser Asp
- Page 291 and 292:
tcatcgcggt tcaaaggcag tggatctggg ac
- Page 293 and 294:
Gly Met Ile Tyr Gly Ser Asp Glu Thr
- Page 295 and 296:
122 Met Asp Thr Arg Ala Pro Thr Gln
- Page 297 and 298:
1 5 128 16 PRT Oryctolagus cuni
- Page 299 and 300:
Oryctolagus cuniculus 136 tacatttg
- Page 301 and 302:
1 5 142 11 PRT Oryctolagus cuni
- Page 303 and 304:
150 33 DNA Oryctolagus cuniculus
- Page 305 and 306:
Arg Gly Gly Tyr Ala Ser Gly Gly Tyr
- Page 307 and 308:
aaggggctgg agtggatcgg atacatttgg ag
- Page 309 and 310:
Met Glu Thr Gly Leu Arg Trp Leu Leu
- Page 311 and 312:
gtcaccatca attgccagtc cagtcagagt gt
- Page 313 and 314:
50 55 60 Pro Pro Lys Leu Leu Ile Ty
- Page 315 and 316:
Gly 193 11 PRT Oryctolagus cuni
- Page 317 and 318:
201 gggatttatt ctgataataa ttattatgc
- Page 319 and 320:
1 5 207 6 PRT Oryctolagus cunic
- Page 321 and 322:
18 DNA Oryctolagus cuniculus 215
- Page 323 and 324:
220 Gln Ala Ser Gln Ser Val Ser Ser
- Page 325 and 326:
DNA Oryctolagus cuniculus 228 cag
- Page 327 and 328:
35 40 45 Ser Tyr Trp Met Cys Trp Va
- Page 329 and 330:
ggtgattgtt atgct 375 243 357 DNA
- Page 331 and 332:
Leu Thr Ile Thr Asp Val Gln Cys Asp
- Page 333 and 334:
1 5 10 258 369 DNA Oryctolagus
- Page 335 and 336:
Met Asp Thr Arg Ala Pro Thr Gln Leu
- Page 337 and 338:
1 5 272 16 PRT Oryctolagus cuni
- Page 339 and 340:
DNA Oryctolagus cuniculus 280 gtc
- Page 341 and 342:
Leu Ala Ser Thr Leu Ala Ser 1 5 28
- Page 343 and 344:
ctggcatcta ctctggcatc t 21 294 30
- Page 345 and 346:
Arg Thr Ser Asp Ile Phe Tyr Tyr Arg
- Page 347 and 348:
ccgacaaccg aggacacggc cacctatttc tg
- Page 349 and 350:
Val Gln Cys Gln Ser Val Glu Glu Ser
- Page 351 and 352:
gtcaccatca actgccagtc cagtcagagt gt
- Page 353 and 354:
50 55 60 Pro Pro Lys Leu Leu Ile Ty
- Page 355 and 356:
Ile Ile Ser Ser Ser Gly Ser Thr Tyr
- Page 357 and 358:
Oryctolagus cuniculus 345 gggggtgc
- Page 359 and 360:
Oryctolagus cuniculus 350 Gln Gln
- Page 361 and 362:
358 caacagggtt atagtagtag ttatgttga
- Page 363 and 364:
13 PRT Oryctolagus cuniculus 364
- Page 365 and 366:
caaatgacca gtctgacagc cgcggacacg gc
- Page 367 and 368:
Val Gln Cys Gln Ser Leu Glu Glu Ser
- Page 369 and 370:
gtcaccatca agtgccaggc cagtcagagc at
- Page 371 and 372:
Gly Gln Pro Pro Lys Leu Leu Ile Tyr
- Page 373 and 374:
1 5 10 15 Gly 401 14 PRT Orycto
- Page 375 and 376:
DNA Oryctolagus cuniculus 409 gaa
- Page 377 and 378:
Gln Cys Thr Tyr Gly Thr Ile Ser Ile
- Page 379 and 380:
423 15 DNA Oryctolagus cuniculus
- Page 381 and 382:
Gln Ala Ser Glu Asp Ile Glu Ser Tyr
- Page 383 and 384:
caggccagtg aggacattga aagctatcta gc
- Page 385 and 386:
Trp Ile Gly Phe Ile Asn Thr Gly Gly
- Page 387 and 388:
451 atggagactg ggctgcgctg gcttctcct
- Page 389 and 390:
459 126 PRT Oryctolagus cuniculu
- Page 391 and 392:
Oryctolagus cuniculus 466 atggacac
- Page 393 and 394:
20 25 30 Val Ser Ala Ala Val Gly Gl
- Page 395 and 396:
Oryctolagus cuniculus 480 Ile Ile
- Page 397 and 398:
489 45 DNA Oryctolagus cuniculus
- Page 399 and 400:
Oryctolagus cuniculus 494 Gln Gln
- Page 401 and 402:
502 caacagggtg ctactgtgta tgatattga
- Page 403 and 404:
Oryctolagus cuniculus 508 Gln Ala
- Page 405 and 406:
Oryctolagus cuniculus 516 caggccag
- Page 407 and 408:
Asn Tyr Tyr Ile Gln Trp Val Arg Gln
- Page 409 and 410:
DNA Oryctolagus cuniculus 531 atg
- Page 411 and 412:
Gln Gly Tyr Tyr Ser Gly Val Ile Asn
- Page 413 and 414:
366 DNA Oryctolagus cuniculus 54
- Page 415 and 416:
1 5 10 15 Leu Pro Gly Ala Arg Cys A
- Page 417 and 418:
17 PRT Oryctolagus cuniculus 560
- Page 419 and 420:
DNA Oryctolagus cuniculus 568 tac
- Page 421 and 422:
Ser Ala Ser Thr Leu Ala Ser 1 5 57
- Page 423 and 424:
582 36 DNA Oryctolagus cuniculus
- Page 425 and 426:
20 25 30 Phe Pro Glu Pro Val Thr Va
- Page 427 and 428:
590 15 PRT Homo sapiens 590 Val
- Page 429 and 430:
599 Ile Arg Tyr Ile Leu Asp Gly Ile
- Page 431 and 432:
609 15 PRT Homo sapiens 609 Glu
- Page 433 and 434:
Homo sapiens 618 Lys Ile Ile Thr G
- Page 435 and 436:
1 5 10 15 628 15 PRT Homo sapie
- Page 437 and 438:
PRT Homo sapiens 637 Thr Asn Ala
- Page 439 and 440:
1 5 10 15 647 111 PRT Oryctolag
- Page 441 and 442:
35 40 45 Tyr Lys Ala Ser Ser Leu Gl
- Page 443 and 444:
Arg 654 97 PRT Homo sapiens 65
- Page 445 and 446:
120 PRT Artificial sequence Huma
- Page 447 and 448:
Val Ser Ala Ala Val Gly Gly Thr Val
- Page 449 and 450:
Ser Leu Arg Leu Ser Cys Ala Ala Ser
- Page 451 and 452:
Ser Leu Arg Leu Ser Cys Ala Ala Ser
- Page 453 and 454:
Arg Val Thr Ile Thr Cys Gln Ala Ser
- Page 455 and 456:
85 90 95 Leu Lys Met Thr Ser Leu Th
- Page 457 and 458:
65 70 75 80 Ala Lys Gly Arg Phe Thr
- Page 459 and 460:
50 55 60 Glu Trp Ile Gly Phe Ile Th
- Page 461 and 462:
35 40 45 Ser Tyr Ala Met Ser Trp Va
- Page 463 and 464:
20 25 30 Gly Thr Pro Leu Thr Leu Th
- Page 465 and 466:
Met Glu Thr Gly Leu Arg Trp Leu Leu
- Page 467 and 468:
Leu Gly Cys Leu Val Lys Asp Tyr Phe
- Page 469 and 470:
Leu Gly Cys Leu Val Lys Asp Tyr Phe
- Page 471 and 472:
Arg Glu Ala Lys Val Gln Trp Lys Val
- Page 473 and 474:
700 360 DNA Oryctolagus cuniculu
- Page 475 and 476:
Oryctolagus cuniculus 703 gaggtgca
- Page 477 and 478:
Ser Arg Thr Pro Glu Val Thr Cys Val
- Page 479 and 480:
115 120 125 Arg Thr Val Ala Ala Pro
- Page 481 and 482:
100 105 110 Cys Ala Arg Asp Asp Ser
- Page 483 and 484:
Asp Asp Phe Ala Thr Tyr Tyr Cys Gln
- Page 485 and 486:
Gly 719 330 PRT Artificial Sequ
- Page 487 and 488:
721 gcctatgata tgacccagac tccagcctc
- Page 489 and 490:
20 25 30 Ser Asp Thr Ser Tyr Val Se
- Page 491 and 492:
Tyr Arg Ala Glu Arg Ser Lys Thr Phe
- Page 493 and 494:
225 230 235 240 Lys Leu Thr Trp Thr
- Page 495:
725 730 735 Ser Arg Pro Ser Ile Ser